BiotechTube

CDP870

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Active Rheumatoid Arthritis

Conditions

Active Rheumatoid Arthritis

Trial Timeline

Jan 1, 2011 → May 1, 2013

NCT ID
NCT02586246

About CDP870

CDP870 is a phase 3 stage product being developed by Astellas Pharma for Active Rheumatoid Arthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT02586246. Target conditions include Active Rheumatoid Arthritis.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT02586246Phase 3Completed

Competing Products

20 competing products in Active Rheumatoid Arthritis

See all competitors
ProductCompanyStageHype Score
CT-P13 SC Auto-Injector + Placebo Auto-InjectorCelltrionPhase 3
77
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
77
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
77
Afimkibart + PlaceboChugai PharmaceuticalPhase 3
77
mirabegron + solifenacinAstellas PharmaApproved
85
Mirabegron + PlaceboAstellas PharmaApproved
85
SolifenacinAstellas PharmaApproved
85
Mirabegron + Tolterodine + Placebo to Mirabegron + Placebo to TolterodineAstellas PharmaPhase 3
77
solifenacin succinateAstellas PharmaPhase 3
77
SolifenacinAstellas PharmaPre-clinical
23
BetanisAstellas PharmaPre-clinical
23
SolifenacinAstellas PharmaApproved
85
SolifenacinAstellas PharmaPhase 2
52
Mirabegron + Tolterodine ERAstellas PharmaApproved
85
mirabegron + solifenacin + darifenacin + imidafenacin + tolterodine + oxybutynin + trospium + fesoterodine + propiverineAstellas PharmaPre-clinical
23
Alpha blocker + placebo + solifenacinAstellas PharmaApproved
85
warfarin + YM178Astellas PharmaPhase 1
33
Solifenacin succinateAstellas PharmaPhase 3
77
solifenacin succinate + tolterodineAstellas PharmaPhase 3
77
Mirabegron tablet + Solifenacin tablet + Propiverine tablet + Imidafenacin tablet + Tolterodine capsuleAstellas PharmaApproved
85

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85